HRP20151344T1 - Kristalni oblik slobodne baze bifenilnog spoja - Google Patents
Kristalni oblik slobodne baze bifenilnog spoja Download PDFInfo
- Publication number
- HRP20151344T1 HRP20151344T1 HRP20151344TT HRP20151344T HRP20151344T1 HR P20151344 T1 HRP20151344 T1 HR P20151344T1 HR P20151344T T HRP20151344T T HR P20151344TT HR P20151344 T HRP20151344 T HR P20151344T HR P20151344 T1 HRP20151344 T1 HR P20151344T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound according
- ester
- crystalline
- biphenyl
- preparation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/124—Aerosols; Foams characterised by the propellant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
- C07D211/64—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having an aryl radical as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22580309P | 2009-07-15 | 2009-07-15 | |
| EP10732616.7A EP2453894B1 (en) | 2009-07-15 | 2010-07-14 | Crystalline freebase form of a biphenyl compound |
| PCT/US2010/041903 WO2011008809A1 (en) | 2009-07-15 | 2010-07-14 | Crystalline freebase forms of a biphenyl compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20151344T1 true HRP20151344T1 (hr) | 2016-01-01 |
Family
ID=42562758
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20151344TT HRP20151344T1 (hr) | 2009-07-15 | 2010-07-14 | Kristalni oblik slobodne baze bifenilnog spoja |
Country Status (20)
| Country | Link |
|---|---|
| US (12) | US8541451B2 (https=) |
| EP (2) | EP2453894B1 (https=) |
| JP (4) | JP5651174B2 (https=) |
| KR (1) | KR101742252B1 (https=) |
| CN (1) | CN102470130B (https=) |
| AU (1) | AU2010273514B2 (https=) |
| BR (1) | BR112012000890A2 (https=) |
| CA (2) | CA2765621C (https=) |
| DK (1) | DK2453894T3 (https=) |
| ES (2) | ES2557553T3 (https=) |
| HR (1) | HRP20151344T1 (https=) |
| HU (1) | HUE026414T2 (https=) |
| IL (1) | IL216995A (https=) |
| MX (1) | MX2012000682A (https=) |
| PL (2) | PL2987490T3 (https=) |
| PT (1) | PT2453894E (https=) |
| SG (2) | SG178036A1 (https=) |
| SI (1) | SI2453894T1 (https=) |
| SM (1) | SMT201600019B (https=) |
| WO (1) | WO2011008809A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI341836B (en) | 2004-03-11 | 2011-05-11 | Theravance Inc | Biphenyl compounds useful as muscarinic receptor antagonists |
| DK2453894T3 (en) | 2009-07-15 | 2016-01-25 | Theravance Biopharma R&D Ip Llc | Crystalline free base of a biphenyl compound |
| SG186708A1 (en) * | 2010-07-13 | 2013-02-28 | Theravance Inc | Process for preparing a biphenyl-2-ylcarbamic acid |
| SI2958916T1 (sl) * | 2013-02-21 | 2018-11-30 | Pfizer Inc. | Trdne oblike selektivnih zaviralcev CDK4/6 |
| WO2015070366A1 (en) | 2013-11-12 | 2015-05-21 | Merck Sharp & Dohme Corp. | Aryl linked imidazole and triazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug |
| WO2020047225A1 (en) | 2018-08-30 | 2020-03-05 | Theravance Biopharma R&D Ip, Llc | Methods for treating chronic obstructive pulmonary disease |
| CN112694434B (zh) * | 2020-12-29 | 2023-06-16 | 浙江和泽医药科技股份有限公司 | 一种雷芬那辛新中间体及其活性亲电砌块和雷芬那辛的新制备方法 |
| CN118401497A (zh) | 2021-12-09 | 2024-07-26 | 医药化学公司 | 雷芬那辛的结晶型丙酮溶剂化物 |
| CN114276290B (zh) * | 2021-12-24 | 2024-05-28 | 浙江和泽医药科技股份有限公司 | 一种雷芬那辛无水晶型及其制备方法 |
| CN117180235A (zh) * | 2023-09-19 | 2023-12-08 | 山东京卫制药有限公司 | 一种无定型雷芬那辛吸入制剂 |
| CN117263849A (zh) * | 2023-09-19 | 2023-12-22 | 山东京卫制药有限公司 | 一种雷芬那辛三水合物晶型及其制备方法 |
| CN117263848A (zh) * | 2023-09-19 | 2023-12-22 | 山东京卫制药有限公司 | 一种雷芬那辛的吸入喷雾剂 |
| US20250136550A1 (en) | 2023-10-27 | 2025-05-01 | Theravance Biopharma R&D Ip, Llc | Processes for preparing revefenacin and compositions comprising the same |
| CN117700354A (zh) * | 2023-12-12 | 2024-03-15 | 江苏百奥信康医药科技有限公司 | 一种雷芬那辛的晶体形式及其制备方法 |
| CN119775192B (zh) * | 2024-12-31 | 2025-11-28 | 山东京卫制药有限公司 | 一种三苯乙酸雷芬那辛晶型及其制备方法 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2425983C3 (de) * | 1973-06-12 | 1978-09-14 | Toyama Chemical Co. Ltd., Tokio | Sulfonsäuresalze von Acylcholinen, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzung |
| BR8007911A (pt) | 1979-12-06 | 1981-06-16 | Glaxo Group Ltd | Inalador aperfeicoado |
| DE3274065D1 (de) | 1981-07-08 | 1986-12-11 | Draco Ab | Powder inhalator |
| DE3682457D1 (de) | 1985-07-30 | 1991-12-19 | Glaxo Group Ltd | Geraet zur verabreichung von medikamenten an patienten. |
| US5225183A (en) | 1988-12-06 | 1993-07-06 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
| SK280968B6 (sk) | 1990-03-02 | 2000-10-09 | Glaxo Group Limited | Balenie medikamentu na použite v inhalačnom prístroji |
| US6006745A (en) | 1990-12-21 | 1999-12-28 | Minnesota Mining And Manufacturing Company | Device for delivering an aerosol |
| US5874063A (en) | 1991-04-11 | 1999-02-23 | Astra Aktiebolag | Pharmaceutical formulation |
| WO1992022286A1 (en) | 1991-06-12 | 1992-12-23 | Minnesota Mining And Manufacturing Company | Albuterol sulfate suspension aerosol formulations |
| US5337740A (en) | 1991-08-01 | 1994-08-16 | New England Pharmaceuticals, Inc. | Inhalation devices |
| EP0617610B1 (en) | 1991-12-18 | 1997-03-19 | Minnesota Mining And Manufacturing Company | Suspension aerosol formulations |
| US5239993A (en) | 1992-08-26 | 1993-08-31 | Glaxo Inc. | Dosage inhalator providing optimized compound inhalation trajectory |
| US5415162A (en) | 1994-01-18 | 1995-05-16 | Glaxo Inc. | Multi-dose dry powder inhalation device |
| WO1995021820A1 (en) | 1994-02-10 | 1995-08-17 | Yamanouchi Pharmaceutical Co., Ltd. | Novel carbamate derivative and medicinal composition containing the same |
| US5983956A (en) | 1994-10-03 | 1999-11-16 | Astra Aktiebolag | Formulation for inhalation |
| US5637820A (en) * | 1995-01-06 | 1997-06-10 | Wittman; Kenneth L. | Stringed instrument with on-board tuner |
| SE9501384D0 (sv) | 1995-04-13 | 1995-04-13 | Astra Ab | Process for the preparation of respirable particles |
| MX9707864A (es) | 1995-04-14 | 1997-11-29 | Glaxo Wellcome Inc | Inhalador de dosis medida por salmeterol. |
| US6040344A (en) | 1996-11-11 | 2000-03-21 | Sepracor Inc. | Formoterol process |
| AU9281298A (en) | 1997-10-01 | 1999-04-23 | Kyowa Hakko Kogyo Co. Ltd. | Benzodioxole derivatives |
| JP2002506856A (ja) | 1998-03-14 | 2002-03-05 | ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング | フタラジノンpdeiii/iv阻害剤 |
| ID27887A (id) | 1998-04-18 | 2001-05-03 | Glaxo Group Ltd | Formulasi aerosol farmasi |
| GB9808802D0 (en) | 1998-04-24 | 1998-06-24 | Glaxo Group Ltd | Pharmaceutical formulations |
| SE9804000D0 (sv) | 1998-11-23 | 1998-11-23 | Astra Ab | New composition of matter |
| US6693202B1 (en) * | 1999-02-16 | 2004-02-17 | Theravance, Inc. | Muscarinic receptor antagonists |
| PT1169019E (pt) | 1999-04-14 | 2003-07-31 | Glaxo Group Ltd | Formulacao farmaceutica em aerossol |
| UA73965C2 (en) | 1999-12-08 | 2005-10-17 | Theravance Inc | b2 ADRENERGIC RECEPTOR ANTAGONISTS |
| GB0103630D0 (en) | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
| EP1366025B1 (en) | 2001-03-08 | 2007-06-27 | Glaxo Group Limited | Agonists of beta-adrenoreceptors |
| JP4143413B2 (ja) | 2001-03-22 | 2008-09-03 | グラクソ グループ リミテッド | β2−アドレナリン受容体アゴニストとしてのホルムアニリド誘導体 |
| US20030018019A1 (en) * | 2001-06-23 | 2003-01-23 | Boehringer Ingelheim Pharma Kg | Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics |
| ES2438985T3 (es) | 2001-09-14 | 2014-01-21 | Glaxo Group Limited | Formulación de inhalación que comprende derivados de fenetanolamina para el tratamiento de enfermedades respiratorias |
| US6653323B2 (en) | 2001-11-13 | 2003-11-25 | Theravance, Inc. | Aryl aniline β2 adrenergic receptor agonists |
| PE20050973A1 (es) * | 2003-10-29 | 2005-11-19 | Theravance Inc | Sales de acido naftalen-1,5-disulfonico de un compuesto de 4-amino-1-(piridilmetil)piperidina como antagonistas de receptores muscarinicos |
| TWI341836B (en) | 2004-03-11 | 2011-05-11 | Theravance Inc | Biphenyl compounds useful as muscarinic receptor antagonists |
| TW200540154A (en) * | 2004-06-10 | 2005-12-16 | Theravance Inc | Crystalline form of a substituted pyrrolidine compound |
| US20060205949A1 (en) * | 2005-03-10 | 2006-09-14 | Theravance, Inc. | Crystalline forms of a biphenyl compound |
| TWI372749B (en) | 2005-03-10 | 2012-09-21 | Theravance Inc | Crystalline forms of a biphenyl compound |
| US7465870B1 (en) * | 2008-03-11 | 2008-12-16 | Homan Randy W | Illuminated heart-shaped guitar with strobe lights and a modified bridge |
| DK2453894T3 (en) * | 2009-07-15 | 2016-01-25 | Theravance Biopharma R&D Ip Llc | Crystalline free base of a biphenyl compound |
| SG186708A1 (en) | 2010-07-13 | 2013-02-28 | Theravance Inc | Process for preparing a biphenyl-2-ylcarbamic acid |
-
2010
- 2010-07-14 DK DK10732616.7T patent/DK2453894T3/en active
- 2010-07-14 AU AU2010273514A patent/AU2010273514B2/en active Active
- 2010-07-14 HR HRP20151344TT patent/HRP20151344T1/hr unknown
- 2010-07-14 CA CA2765621A patent/CA2765621C/en active Active
- 2010-07-14 CA CA2989129A patent/CA2989129C/en active Active
- 2010-07-14 EP EP10732616.7A patent/EP2453894B1/en active Active
- 2010-07-14 WO PCT/US2010/041903 patent/WO2011008809A1/en not_active Ceased
- 2010-07-14 HU HUE10732616A patent/HUE026414T2/hu unknown
- 2010-07-14 BR BR112012000890A patent/BR112012000890A2/pt not_active Application Discontinuation
- 2010-07-14 CN CN2010800304581A patent/CN102470130B/zh active Active
- 2010-07-14 ES ES10732616.7T patent/ES2557553T3/es active Active
- 2010-07-14 SG SG2012003067A patent/SG178036A1/en unknown
- 2010-07-14 PL PL15178848T patent/PL2987490T3/pl unknown
- 2010-07-14 SG SG10201407913UA patent/SG10201407913UA/en unknown
- 2010-07-14 KR KR1020127004005A patent/KR101742252B1/ko active Active
- 2010-07-14 US US12/835,964 patent/US8541451B2/en active Active
- 2010-07-14 EP EP15178848.6A patent/EP2987490B1/en active Active
- 2010-07-14 JP JP2012520734A patent/JP5651174B2/ja active Active
- 2010-07-14 PT PT107326167T patent/PT2453894E/pt unknown
- 2010-07-14 ES ES15178848.6T patent/ES2639642T3/es active Active
- 2010-07-14 SI SI201031095T patent/SI2453894T1/sl unknown
- 2010-07-14 MX MX2012000682A patent/MX2012000682A/es active IP Right Grant
- 2010-07-14 PL PL10732616T patent/PL2453894T3/pl unknown
-
2011
- 2011-12-15 IL IL216995A patent/IL216995A/en active IP Right Grant
-
2013
- 2013-08-22 US US13/973,174 patent/US8921396B2/en active Active
-
2014
- 2014-10-07 JP JP2014206123A patent/JP6338505B2/ja active Active
- 2014-11-19 US US14/547,455 patent/US9226896B2/en active Active
-
2015
- 2015-11-04 JP JP2015216372A patent/JP2016026214A/ja active Pending
- 2015-12-01 US US14/955,515 patent/US9415041B2/en active Active
-
2016
- 2016-01-20 SM SM201600019T patent/SMT201600019B/it unknown
- 2016-07-11 US US15/206,877 patent/US9765028B2/en active Active
-
2017
- 2017-07-10 JP JP2017134632A patent/JP2017171692A/ja active Pending
- 2017-08-15 US US15/677,264 patent/US10100013B2/en active Active
-
2018
- 2018-09-13 US US16/130,079 patent/US10550081B2/en active Active
-
2019
- 2019-12-16 US US16/715,225 patent/US11008289B2/en active Active
-
2021
- 2021-04-15 US US17/301,820 patent/US11691948B2/en active Active
-
2022
- 2022-06-15 US US17/841,567 patent/US11649209B2/en active Active
-
2023
- 2023-05-19 US US18/199,812 patent/US11858898B2/en active Active
-
2024
- 2024-07-02 US US18/762,102 patent/US20250179019A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20151344T1 (hr) | Kristalni oblik slobodne baze bifenilnog spoja | |
| EP1797099B1 (en) | Piperidinylamino-thieno[2,3-d] pyrimidine compounds | |
| KR102120883B1 (ko) | 인간 히스톤 메틸트랜스퍼라제 ezh2 억제제의 염 형태 | |
| JP4995076B2 (ja) | Gsk−3阻害剤 | |
| JP2012533550A5 (https=) | ||
| HRP20130192T1 (hr) | Kristalni oblik bifenilnog spoja | |
| ME02066B (me) | Kristalni oblici hidrohloridne soli ( 4a-r,9a-s)- 1-( 1h-benzoimidazol- s-karbonil)- 2,3,4,4a,9,9a-heksahidr0- 1h-inden0[2,1-b]piridin-6-karbonitrila i njihova upotreba kao inhibitora hsd 1 | |
| WO2020163405A1 (en) | Methods and compositions for modulating splicing | |
| HRP20100035T1 (hr) | Kristalni oblici bifenilnog spoja | |
| CN101255169A (zh) | 普拉格雷盐及其制备方法 | |
| JP2020518662A (ja) | 化合物の結晶多形、その製造方法及び用途 | |
| TWI574687B (zh) | 具有鋅結合部份之刺蝟拮抗劑 | |
| MA27600A1 (fr) | Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable | |
| MX2011008858A (es) | Compuestos de diarilhidantoina y diariltiohidantoina especificos. | |
| HRP20151338T1 (hr) | [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-[7-fluoro-1-(2-metoksi-etil)-4trifluorometoksi-1h-indol-3-il]metanon kao inhibitor triptaze mastocita | |
| JPWO2014168103A1 (ja) | ピロール誘導体の結晶及びその製造方法 | |
| JP2013541592A5 (https=) | ||
| CN110680823B (zh) | 联苯磷酸酯类化合物的用途 | |
| CN109280030B (zh) | 苯骈氮杂烷基芳基哌嗪衍生物及在制备药物中的应用 | |
| ME02480B (me) | Optimizirana sinteza čistih, nepolimorfnih, kristalnih žučnih kiselina sa određenom veličinom čestica | |
| CN103664793B (zh) | 阿奇沙坦中间体及其制备方法 | |
| CN103664792B (zh) | 阿奇沙坦中间体及其制备方法 | |
| JP6927548B2 (ja) | ある種のタンパク質キナーゼ阻害剤 | |
| CN101595099A (zh) | 晶体盐酸度洛西汀 | |
| CA2583353A1 (en) | Thienopyridinone compounds and methods of treatment |